{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:10:56Z","timestamp":1790349056971,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Perioperative dosing recommendations vary across Nordic haemophilia treatment centres (HTCs) for extended half\u2010life (EHL) factor concentrates in haemophilia A\/B (HA\/HB) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To summarise Nordic real\u2010world surgical experiences with EHL recombinant factor VIII\/IX Fc (rFVIIIFc\/rFIXFc) fusion proteins using retrospective data from clinical records at four HTCs in Finland, Sweden and Norway.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Factor dosing and surgical outcomes were recorded from HA\/HB patients who underwent surgery and were treated with rFVIIIFc\/rFIXFc. Perioperative factor dosing regimens were clinician\u2010determined based on local practises.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty five surgeries were performed on 20 patients, all covered by bolus injections except one minor HA surgery; eight minor surgeries were in paediatric patients. Median preoperative rFVIIIFc dose for major HA surgeries (<jats:italic>n<\/jats:italic>\u00a0=\u00a08) was 48\u00a0IU\/kg (range: 35\u201357), with total consumption up to Day 14 of 427\u00a0IU\/kg (196\u2013568). For the two major HB surgeries (in one patient), preoperative rFIXFc doses were 50\u00a0IU\/kg and 20\u00a0IU\/kg; total consumption up to Day 14 was 130\u00a0IU\/kg and 40\u00a0IU\/kg. Median preoperative rFVIIIFc\/rFIXFc bolus doses for minor HA (<jats:italic>n<\/jats:italic>\u00a0=\u00a010) and HB (<jats:italic>n<\/jats:italic>\u00a0=\u00a04) surgeries were 50\u00a0IU\/kg (24\u201379) and 47\u00a0IU\/kg (40\u201371), with total consumption up to Day 5 of 138\u00a0IU\/kg (49\u2013404) and 100\u00a0IU\/kg (43\u2013125), respectively. Intraoperative and postoperative haemostatic responses were rated as at least good\/excellent for 24\/25 surgeries, with bleeding episodes reported in only three surgeries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Nordic real\u2010world experiences suggest that EHL products can be used safely and effectively for peri\u2010operative haemostasis. Further research is required to develop local dosing guidelines for optimised treatment schedules.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14585","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T12:36:05Z","timestamp":1652704565000},"page":"713-719","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Surgical outcomes in patients with haemophilia A or B receiving extended half\u2010life recombinant factor VIII and IX Fc fusion proteins: Real\u2010world experience in the Nordic countries"],"prefix":"10.1111","volume":"28","author":[{"given":"Anna\u2010Elina","family":"Lehtinen","sequence":"first","affiliation":[{"name":"Coagulation Disorders Unit, Department of Haematology Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Baghaei","sequence":"additional","affiliation":[{"name":"Coagulation Centre, Department of Medicine\/Section of Haematology and Coagulation Sahlgrenska University Hospital and Institute of Medicine, Sahlgrenska Academy, University of Gothenburg  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8500-2483","authenticated-orcid":false,"given":"Jan","family":"Astermark","sequence":"additional","affiliation":[{"name":"Institution for Translational Medicine Lund University and Department for Haematology, Oncology and Radiation Physics, Sk\u00e5ne University Hospital  Malm\u00f6 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l Andr\u00e9","family":"Holme","sequence":"additional","affiliation":[{"name":"Department of Haematology Oslo University Hospital and Institute of Clinical Medicine, University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106073442307"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01950.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_10_5_1","volume-title":"Nordic Hemophilia Council Guideline Working Group","year":"2020"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12887"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13109"},{"key":"e_1_2_10_8_1","first-page":"1","article-title":"Invasive procedures in patients with haemophilia: review of low\u2010dose protocols and experience with extended half\u2010life FVIII and FIX concentrates and non\u2010replacement therapies","volume":"00","author":"Hermans C","year":"2020","journal-title":"Haemophilia"},{"key":"e_1_2_10_9_1","volume-title":"Elocta\u00ae (Efmoroctocog alfa) Summary of Product Characteristics","author":"EMA","year":"2021"},{"key":"e_1_2_10_10_1","volume-title":"Alprolix\u00ae (Eftrenonacog alfa) Summary of Product Characteristics","author":"EMA","year":"2021"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529974"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305074"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12911"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30193-4"},{"issue":"1","key":"e_1_2_10_15_1","first-page":"1","article-title":"Long\u2010acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A","volume":"116","author":"Mahlangu JN","year":"2016","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13112"},{"issue":"1","key":"e_1_2_10_17_1","first-page":"66","article-title":"Successful use of EHL\u2010FIX in hemophilia B carriers with FIX deficiency: a single center experience","volume":"25","author":"Hermans CR","year":"2019","journal-title":"Haemophilia"},{"issue":"1","key":"e_1_2_10_18_1","first-page":"285","article-title":"Extended half\u2010life recombinant factir IXFc is effective in preventing bleeding after major and minor surgery in severe Factor IX deficiency","volume":"3","author":"O'Donovan M","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_10_19_1","unstructured":"LienhartA MeunierS NougierC Which FVIII:c assay for the monitoring of patients with hemophilia undergoing surgery under the cover of FVIII\u2010Fc fusion protein?Presented at: ECTH 2019.Glasgow UK;2019."},{"key":"e_1_2_10_20_1","unstructured":"HellalM AlviA Campbell TaitR Experience of major orthopaedic surgery in severe haemophilia A with extended half life factor FVIII Fc fusion protein.Presented at: WFH 2018 Glasgow UK;2018."},{"key":"e_1_2_10_21_1","first-page":"266127","article-title":"Recombinant factor VIII Fc fusion protein in surgeries in hemophilia A","author":"Patil V","year":"2019","journal-title":"EHA Lib"},{"issue":"1","key":"e_1_2_10_22_1","first-page":"736","article-title":"Continuous infusion of recombinant factor IX Fc fusion protein during major surgery","volume":"1","author":"Kanematsu T","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13557"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13347"},{"issue":"4","key":"e_1_2_10_25_1","first-page":"s542","article-title":"Eftrenonacog alfa (rFIXFc) in major surgery: a case report","volume":"16","author":"Valeri F","year":"2018","journal-title":"Blood Transfus"},{"issue":"5","key":"e_1_2_10_26_1","first-page":"20","article-title":"Surgical prophylaxis using long acting factor concentrate in a cohort of haemophilia patients [W\u2010P\u2010008 (684)]","volume":"24","author":"Abraham A","year":"2018","journal-title":"Haemophilia"},{"issue":"5","key":"e_1_2_10_27_1","first-page":"154","article-title":"Utilization of extended half\u2010life recombinant of Fc\u2010Fusion protein concentrate from WFH donation in Indonesia","volume":"24","author":"Amelia N","year":"2018","journal-title":"Haemophilia"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116160"},{"issue":"4","key":"e_1_2_10_29_1","first-page":"79","article-title":"Clinical and laboratorial evaluation of recombinant FVIII Fc fusion protein treatment in hemophilia A patients: a real\u2010life in a single center","volume":"2016","author":"Echenagucia M","journal-title":"Haemophilia"},{"issue":"1","key":"e_1_2_10_30_1","first-page":"50","article-title":"Use of extended half\u2010life rFVIII\u2010Fc or rFIX\u2010Fc in previously treated patients with hemophilia A or B. A single center experience [PO30]","volume":"25","author":"Ruiz\u2010Saez A","year":"2019","journal-title":"Haemophilia"},{"key":"e_1_2_10_31_1","volume-title":"Avtaler LIS 1712 og 1812a","author":"Helseforetakenes Innkj\u00f8psservice AS (HINAS)","year":"2019"},{"key":"e_1_2_10_32_1","volume-title":"Alprolix ing\u00e5r i h\u00f6gkostnadsskyddet med uppf\u00f6ljningsvillkor","author":"Tandv\u00e5rds\u2010 och l\u00e4kemedelsf\u00f6rm\u00e5nsverket","year":"2018"},{"key":"e_1_2_10_33_1","volume-title":"Elocta ing\u00e5r i h\u00f6gkostnadsskyddet med uppf\u00f6ljningsvillkor","author":"Tandv\u00e5rds\u2010 och l\u00e4kemedelsf\u00f6rm\u00e5nsverket","year":"2016"},{"key":"e_1_2_10_34_1","volume-title":"Reimbursable Authorized Medicinal Products and their Prices","author":"L\u00e4\u00e4kkeiden hintalautakunta","year":"2021"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-199901000-00002"},{"issue":"3","key":"e_1_2_10_36_1","first-page":"01","article-title":"Evaluation of blood loss during the perioperative period in orthopedic and trauma surgery","volume":"7","author":"Ramampisendrahova JB","year":"2021","journal-title":"EPH \u2013 Int J Med Health Sci"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14426"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14585","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14585","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T08:44:26Z","timestamp":1692693866000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/hae.14585"],"URL":"https:\/\/doi.org\/10.1111\/hae.14585","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"2021-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}